• Researcher Profile

    Ross S. Berkowitz, MD

     
    Ross S. Berkowitz, MD

    Top Doctor

     
    Surgical Director, Gynecologic Oncology

    William H. Baker Professor of Gynecology, Harvard Medical School

    Center/Program

    Gynecologic Oncology

    Office phone: 617-732-8843
    Fax: 617-632-3714
    Email: rberkowitz@partners.org

    Preferred contact method: appointment phone

    View Physician Profile
     
     

    Research Department

    Medical Oncology/Solid Tumor Oncology

    Interests

    Abnormal pap smears, Gynecologic oncology, Ovarian tumors, Pelvic tumors, Uterine tumors, Trophoblastic disease

    Area of Research

    Gestational Trophoblastic Disease and Ovarian Carcinogenesis


    Brigham and Women's Hospital
    75 Francis Street
    Boston, MA 02215

    Biography

    Dr. Berkowitz received his MD from Boston University in 1973 and completed residency training in surgery at the Peter Bent Brigham Hospital. He trained in obstetrics and gynecology at the Boston Hospital for Women, where he completed a fellowship in gynecologic oncology. He joined the faculty of Brigham and Women's Hospital in 1980, and is the director of the Gynecologic Oncology Program at Dana-Farber/Partners CancerCare.

    Recent Awards

    • Honorary Member, Hungarian National Academy of Science, 1999

    Research

    Gestational Trophoblastic Disease and Ovarian Carcinogenesis

    Working closely with Dr. Donald P. Goldstein and Marilyn Bernstein, MHP, we are studying the natural history, epidemiology, treatment, and molecular biology of gestational trophoblastic disease. In collaboration with Drs. Shu-Wing Ng, Michael Muto, and Daniel Cramer, we are also pursuing studies of the genetic changes in invasive epithelial ovarian cancer, borderline ovarian tumors, and peritoneal malignancy. The Gynecologic Oncology Laboratory focuses on determining the early genetic changes in the development of ovarian cancer. Using DNA microarray technology, we have identified several promising markers including prostasin and osteopontin, which are elevated in the serum of patients with early ovarian cancer and significantly improve the sensitivity and specitivity of CA125 in the detection of ovarian cancer. Important advances have also been made in the understanding of the early genetic changes in ovarian cancer. Mucinous ovarian cancer is often associated with benign and borderline malignant mucinous epithelium in the same tissue. The same K-ras mutation has been demonstrated in adjacent benign, borderline malignant, and malignant mucinous epithelium in tissues precisely isolated by laser capture microscopy. K-ras mutation may be an early event in mucinous ovarian tumorigenesis, and benign and borderline mucinous epithelium may be a precursor of mucinous carcinoma. Patients with borderline serous ovarian cancer may later develop invasive serous ovarian cancer. By studying p53 and K-ras mutations, we have found that serous borderline ovarian tumor and subsequent invasive serous carcinomas seem to be unrelated. Patients with BRCA1 or BRCA2 mutations have a 20% to 40% risk of developing ovarian cancer and, therefore, prophylactic oophorectomy has been advocated as a preventive strategy. Importantly, papillary serous peritoneal cancer may also develop in patients with BRA1 and BRA2 mutations, and ovaries removed prophylacticly may already harbor occult ovarian malignancy. Placental site trophoblastic tumor (PSTT) is an unusual variant that is relatively resistant to chemotherapy. Based on our clinical experience, patients with nonmetastatic PSTT should undergo hysterectomy as primary therapy. Patients with gestational trophoblastic tumors are commonly cured with chemotherapy while preserving their fertility. Data from more than 500 patients who became pregnant following chemotherapy indicate that the outcome from these pregnancies is about the same as the general population.

View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now